Ikarovec Eyes $1B Deal to Move Eye Gene Therapy In-Office
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
Shajini
NeuroPulse Daily: January 05, 2026
Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD.
NICE Clears MS Treatment Option Suitable During Pregnancy
NICE backs natalizumab for highly active relapsing MS.
NICE Backs Age-Based Blood Test to Spot Ovarian Cancer
NICE proposes age-based CA125 testing to improve early diagnosis.
Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets
NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and … Read more
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.